The United States Food and Drug Administration (FDA) has approved a new drug to treat adult and child cancer patients based on genetic clauses rather than on the type of disease.
The drug of the name Vitrakvi and its scientific name LAROTECTINIB has been approved for the treatment of cancers that can be found anywhere in the body.
NITCAVI is the first drug designed from the first to fight the genetic combat of the disease, regardless of the type of cancer, says NBC.
FDA's approval is an important step in treating cancer, "said Commissioner FDA Scott Gottlieb in a statement." Base of tumor genes, irrespective of where they originate in the body. "
"This will help patients get" timely treatment, "he said.
He said that the drug treats people with different tumors, but has a common genetic mutation, stating that this was not available a decade ago because information about genetic mutations is less than it is now.